The estimated Net Worth of Jeffrey L. Ives is at least $497 Tysiąc dollars as of 15 July 2022. Jeffrey Ives owns over 3,600 units of Cara Therapeutics Inc stock worth over $4,488 and over the last 10 years he sold CARA stock worth over $196,673. In addition, he makes $296,024 as Independent Director at Cara Therapeutics Inc.
Jeffrey has made over 15 trades of the Cara Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,600 units of CARA stock worth $32,580 on 15 July 2022.
The largest trade he's ever made was selling 8,180 units of Cara Therapeutics Inc stock on 12 November 2021 worth over $131,207. On average, Jeffrey trades about 1,585 units every 41 days since 2014. As of 15 July 2022 he still owns at least 15,476 units of Cara Therapeutics Inc stock.
You can see the complete history of Jeffrey Ives stock trades at the bottom of the page.
Dr. Jeffrey L. Ives Ph.D. serves as Independent Director of the Company. From 2008 until 2013, Dr. Ives currently is a Venture Partner at New Leaf Venture Partners, healthcare technology venture firm, and a Principal at NeuroPharma Advisors, LLC., an advisory group focused on companies developing therapeutics for the CNS. Dr. Ives is also currently a director at private pharmaceutical and biotechnology companies, Astrocyte Pharmaceuticals Inc., Acumen Pharmaceuticals, Inc., Pinteon Therapeutics Inc. and Orthogonal Neurosciences, private. Previously, Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a neurodegenerative disease company focused on discovery and development of breakthrough therapies for the treatment and prevention of Alzheimer’s disease from 2008 until 2013. Prior to Satori, Dr. Ives led the CNS, pain and oncology research teams at Pfizer for over two decades and, from 2001 to 2007, he served as a Senior Vice President leading the global Pharmacokinetics, Dynamics and Metabolism organization. Dr. Ives received his doctorate and master degrees from Yale University and received his bachelor of arts degree from Colgate University. His extensive experience leading research and drug development provides him with the qualifications to serve on the Board.
As the Independent Director of Cara Therapeutics Inc, the total compensation of Jeffrey Ives at Cara Therapeutics Inc is $296,024. There are 12 executives at Cara Therapeutics Inc getting paid more, with Joana Goncalves having the highest compensation of $3,736,190.
Jeffrey Ives is 69, he's been the Independent Director of Cara Therapeutics Inc since 2014. There are 1 older and 16 younger executives at Cara Therapeutics Inc. The oldest executive at Cara Therapeutics Inc is Harrison Bains, 76, who is the Independent Director.
Jeffrey's mailing address filed with the SEC is 9th, 107 Elm St, Stamford, CT 06902, USA.
Over the last 11 years, insiders at Cara Therapeutics Inc have traded over $25,200,591 worth of Cara Therapeutics Inc stock and bought 1,874,453 units worth $19,406,983 . The most active insiders traders include Edward Hurwitz, Martin Vogelbaum oraz Ventures Vi Lprmv Vi, L.L.C.... On average, Cara Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $5,343. The most recent stock trade was executed by Christopher Posner on 1 August 2024, trading 4,149 units of CARA stock currently worth $1,452.
cara therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat pain, inflammation and pruritus. cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. cara's most advanced patented compound, cr845, is currently undergoing clinical testing for acute pain and uremic pruritus. this compound possesses analgesic, anti-inflammatory and antipruritic activities appropriate for multiple therapeutic applications. in addition, cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
Cara Therapeutics Inc executives and other stock owners filed with the SEC include: